INT10237

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1989
Last Reported 2008
Negated 1
Speculated 0
Reported most in Abstract
Documents 40
Total Number 45
Disease Relevance 16.00
Pain Relevance 8.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (EDN1) extracellular region (EDN1) cell-cell signaling (EDN1)
cytoplasm (EDN1)
Anatomy Link Frequency
coronary artery 2
endothelium 2
plasma 1
chondrocytes 1
myometrium 1
EDN1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 20 100.00 Very High Very High Very High
Somatostatin 18 100.00 Very High Very High Very High
calcitonin gene related peptide 5 100.00 Very High Very High Very High
substance P 5 100.00 Very High Very High Very High
qutenza 14 99.78 Very High Very High Very High
antagonist 439 99.52 Very High Very High Very High
Inflammation 19 99.16 Very High Very High Very High
Neuropeptide 24 99.08 Very High Very High Very High
ischemia 11 98.52 Very High Very High Very High
Pain 29 97.52 Very High Very High Very High
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 84 100.00 Very High Very High Very High
Cv General 3 Under Development 20 100.00 Very High Very High Very High
Glioma 10 99.84 Very High Very High Very High
Osteoporosis 75 99.80 Very High Very High Very High
Coronary Artery Disease 16 99.76 Very High Very High Very High
Cancer 270 99.60 Very High Very High Very High
INFLAMMATION 20 99.52 Very High Very High Very High
Cardiovascular Disease 20 99.44 Very High Very High Very High
Metastasis 133 99.28 Very High Very High Very High
Natriuresis 18 99.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These data show that bosentan is able to reduce ET-1 binding to the human coronary artery and ET-1 constrictor effects in vitro.
ET-1 Binding (binding) of in coronary artery
1) Confidence 0.48 Published 1995 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 8587420 Disease Relevance 0 Pain Relevance 0.20
This paper aims to demonstrate that there is currently sufficient evidence to suggest that endothelin-1 (ET-1) may play a role in angina and be associated with myocardial ischaemia.
endothelin-1 Binding (associated) of associated with angina and coronary artery disease
2) Confidence 0.48 Published 2001 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 11811372 Disease Relevance 0.68 Pain Relevance 0.48
This paper aims to demonstrate that there is currently sufficient evidence to suggest that endothelin-1 (ET-1) may play a role in angina and be associated with myocardial ischaemia.
ET-1 Binding (associated) of associated with angina and coronary artery disease
3) Confidence 0.48 Published 2001 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 11811372 Disease Relevance 0.68 Pain Relevance 0.48
The aim of this review article is to present the current literature concerning the interaction between endothelin and the various forms of myocardial ischemia, and to explore the significance of such interactions.
endothelin Binding (interaction) of associated with coronary artery disease and ischemia
4) Confidence 0.48 Published 1994 Journal Cardiovasc Drugs Ther Section Abstract Doc Link 7848895 Disease Relevance 0.61 Pain Relevance 0.26
The binding of 125I-endothelin was half-maximally inhibited by cold endothelin at a concentration (IC50) of 140 pM.
endothelin Binding (binding) of
5) Confidence 0.47 Published 1989 Journal Life Sci. Section Abstract Doc Link 2542708 Disease Relevance 0 Pain Relevance 0.34
GPR37 and ETBR-LP2 are related to each other and branch off the endothelin receptors that bind characteristic bicyclic peptides of 21 amino acids containing four cysteines linked by two disulfide bonds.
endothelin Binding (bind) of
6) Confidence 0.47 Published 2002 Journal Genome Biol Section Body Doc Link PMC133447 Disease Relevance 0 Pain Relevance 0.26
An interaction between ET-1 and vascular endothelial growth factor (VEGF) has also been reported, and some positive results of treatment with endothelin receptor blockers have raised interest in these substances as potentially therapeutic agents (Masuzawa et al 2006).
ET-1 Binding (interaction) of
7) Confidence 0.46 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605330 Disease Relevance 1.45 Pain Relevance 0.13
ET-1 binds to the specific endothelin A or endothelin B receptors expressed on chondrocytes [4] and triggers a cascade of intracellular events, including phospholipase C activation [5], an increase in intracellular calcium [6,7], prostaglandin production [8] and nitric oxide (NO) release [9].
ET-1 Binding (binds) of in chondrocytes
8) Confidence 0.43 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065327 Disease Relevance 0.32 Pain Relevance 0.20
We demonstrate that in brachial arteries of steroid exposed offspring: KCl induced contraction is increased after endothelium removal or incubation with inhibitors of nitric oxide synthase or cyclooxygenase; acetylcholine-induced relaxation is increased; sensitivity to endothelin-1 (ET-1) is increased and this effect is decreased by the ETB antagonist BQ-788.
ET-1 Binding (sensitivity) of in endothelium associated with antagonist
9) Confidence 0.36 Published 2006 Journal Pediatr. Res. Section Abstract Doc Link 17065564 Disease Relevance 0 Pain Relevance 0.14
We demonstrate that in brachial arteries of steroid exposed offspring: KCl induced contraction is increased after endothelium removal or incubation with inhibitors of nitric oxide synthase or cyclooxygenase; acetylcholine-induced relaxation is increased; sensitivity to endothelin-1 (ET-1) is increased and this effect is decreased by the ETB antagonist BQ-788.
endothelin-1 Binding (sensitivity) of in endothelium associated with antagonist
10) Confidence 0.36 Published 2006 Journal Pediatr. Res. Section Abstract Doc Link 17065564 Disease Relevance 0 Pain Relevance 0.14
Group A7 is also composed of receptors for peptide ligands: neuromedin, neurotensin, motilin, endothelin, bombesin and the releasing hormones for growth hormone and thyrotropin.
endothelin Binding (ligands) of
11) Confidence 0.36 Published 2002 Journal Genome Biol Section Body Doc Link PMC133447 Disease Relevance 0 Pain Relevance 0.27
Characterization of functional endothelin receptors in the porcine myometrium.
endothelin Binding (Characterization) of in myometrium
12) Confidence 0.36 Published 2000 Journal Peptides Section Title Doc Link 10822110 Disease Relevance 0 Pain Relevance 0.09
Actions of endothelin and corticotropin releasing factor in the guinea-pig ileum: no evidence for an interaction with capsaicin-sensitive neurons.
endothelin Neg (no) Binding (interaction) of in neurons associated with qutenza
13) Confidence 0.36 Published 2003 Journal Neuropeptides Section Title Doc Link 12906840 Disease Relevance 0 Pain Relevance 0.76
Emerging experimental and clinical data demonstrate that interfering with endothelin receptors provides an opportunity for the development of rational combinatorial approaches using endothelin receptor antagonists in combination with chemotherapy or molecularly targeted therapy.
endothelin Binding (interfering) of associated with antagonist
14) Confidence 0.36 Published 2008 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 18758494 Disease Relevance 0.55 Pain Relevance 0.18
Unlabeled bosentan prevented [125I]ET-1 binding to this vessel in a concentration-dependent manner, and functional studies indicated that bosentan antagonizes ET-1--induced constriction.
ET-1 Binding (binding) of
15) Confidence 0.36 Published 1995 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 8587420 Disease Relevance 0 Pain Relevance 0.17
The H1 antagonist terfenadine (120 mg po) significantly reduced the flare area associated with endothelin 1: flare 5 min after intradermal endothelin (10 pmol, placebo treated), 668 +/- 405 mm2; terfenadine treated, 201 +/- 257 mm2 (P less than 0.05).
endothelin Binding (associated) of associated with antagonist
16) Confidence 0.36 Published 1991 Journal J. Appl. Physiol. Section Abstract Doc Link 1707048 Disease Relevance 0.23 Pain Relevance 0.29
By immunohistochemical analysis and immunofluorescence, endothelin-converting enzyme-1 (ECE-1), the enzyme that synthesizes ET-1, is localized to five distinct cell populations in the human placenta: (1) the endothelial cells lining the maternal basal plate blood vessels, (2) the intermediate trophoblasts, (3) the endothelial cells lining the chorionic villous blood vessels, (4) the chorionic villous stromal cells and (5) the chorionic villous trophoblasts.
ET-1 Binding (localized) of in endothelial cells
17) Confidence 0.35 Published 2000 Journal Placenta Section Abstract Doc Link 10736246 Disease Relevance 0.08 Pain Relevance 0
High-affinity binding sites for endothelin have been found in a human placenta membrane preparation. 125I-endothelin bound to placenta membranes at 20 degrees C with an association half-time of 30 min, whereas the binding was only slowly reversed with a dissociation half-time of 250 min.
endothelin Binding (binding) of in placenta
18) Confidence 0.35 Published 1989 Journal Life Sci. Section Abstract Doc Link 2542708 Disease Relevance 0 Pain Relevance 0
This effect occurs within minutes following a challenge with ET-1, and disappears after 45 and 60 min for the p-38 and SAP/JNK kinases, respectively.
ET-1 Binding (challenge) of
19) Confidence 0.33 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065327 Disease Relevance 0.08 Pain Relevance 0.04
This suggests that these inhibitors are specific for the ET-1-activated pathways since they do not affect the basal levels of MMP-1 and MMP-13.
ET-1-activated Binding (specific) of
20) Confidence 0.33 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065327 Disease Relevance 0.21 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox